Since CDK4/6 inhibitors inevitably develop drug resistance (Pandey et al., 2019), and monotherapy with CDK4/6 inhibitors, including abemaciclib is not very effective for the treatment of lung cancer patients (Gopalan et al., 2018), drug combination is thus a reasonable therapeutic strategy. This evidence concerns the gene CDK4 and lung carcinoma.